Rachel Abbott

Company: Pan Cancer T

Job title: Chief Executive Officer

Seminars:

Panel Discussion: A Commercial TCR-T & TCR Bispecific – What’s Next? 12:00 pm

• Discussing engineering methods to alter T-cell or bispecific properties to increase trafficking to tumor sites and enable prolonged killing • Inhibiting immune suppression pathways to improve cell survival • Considering implications of multi-engineering on cell viability and patient safety to mitigate adverse effectsRead more

day: Day 2

Spearheading Discovery & Validation of Novel Targets to Expand Indication & Treatment Potential 9:01 am

TCR-based therapies open a huge pool of intracellular target antigens that cannot be targeted by other therapeutics, but currently, success has only been seen in a small portion of this target repertoire. Therefore, it is imperative to diversify the range of effective targets, as well as to validate their tumor-specificity to mitigate against off-target effects…Read more

day: Workshop A